Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A van Royen

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|December 19, 2001
Rigidity decreases resting tremor intensity in Parkinson's disease: A [(123)I]beta-CIT SPECT study in early, nonmedicated patientsA Winogrodzka, R C Wagenaar, P Bergmans, et al.
Nuclear Medicine and Biology|November 1, 1995
Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's diseaseR J Vermeulen, E C Wolters, G Tissingh, et al.
Synapse (New York, N.Y.)|July 1, 1996
In vitro and in vivo characterization of newly developed iodinated 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]piperazine derivatives in rats: limited value as dopamine transporter SPECT ligandsL J Rijks, J Booij, T Doornbos, et al.
Nuclear Medicine and Biology|December 24, 1998
New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 2: In vivo pharmacological characterizationL J Rijks, J C van den Bos, P A van Doremalen, et al.
Nuclear Medicine Communications|March 22, 2001
Quantitative analysis of 99Tcm-sestamibi myocardial perfusion SPECT using a three-dimensional reference heart: a comparison with experienced observersH J Verberne, J B Habraken, E A van Royen, et al.
Clinical Neurology and Neurosurgery|January 1, 1986
Functional brain imaging with I123-amphetamine. First experience in the NetherlandsJ F de Bruïne, E A van Royen, F van Weeren, et al.
Kidney International|May 1, 1993
Complement activation during OKT3 treatment: a possible explanation for respiratory side effectsM H Raasveld, F J Bemelman, P T Schellekens, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1996
99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphomaS F Vervoordeldonk, J Heikens, W T Goedemans, et al.
European Journal of Nuclear Medicine|August 1, 1996
Cardiac iodine-123 metaiodobenzylguanidine uptake in animals with diabetes mellitus and/or hypertensionE A Dubois, K L Kam, G A Somsen, et al.
Bone Marrow Transplantation|November 5, 2003
Nonlethal transfusion associated graft-versus-host disease in a severe combined immunodeficient patientA van Royen-Kerkhof, N M Wulffraat, S S M Kamphuis, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Movement Disorders : Official Journal of the Movement Disorder Society|December 19, 2001
Rigidity decreases resting tremor intensity in Parkinson's disease: A [(123)I]beta-CIT SPECT study in early, nonmedicated patientsA Winogrodzka, R C Wagenaar, P Bergmans, et al.
Nuclear Medicine and Biology|November 1, 1995
Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's diseaseR J Vermeulen, E C Wolters, G Tissingh, et al.
Synapse (New York, N.Y.)|July 1, 1996
In vitro and in vivo characterization of newly developed iodinated 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]piperazine derivatives in rats: limited value as dopamine transporter SPECT ligandsL J Rijks, J Booij, T Doornbos, et al.
Nuclear Medicine and Biology|December 24, 1998
New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 2: In vivo pharmacological characterizationL J Rijks, J C van den Bos, P A van Doremalen, et al.
Nuclear Medicine Communications|March 22, 2001
Quantitative analysis of 99Tcm-sestamibi myocardial perfusion SPECT using a three-dimensional reference heart: a comparison with experienced observersH J Verberne, J B Habraken, E A van Royen, et al.
Clinical Neurology and Neurosurgery|January 1, 1986
Functional brain imaging with I123-amphetamine. First experience in the NetherlandsJ F de Bruïne, E A van Royen, F van Weeren, et al.
Kidney International|May 1, 1993
Complement activation during OKT3 treatment: a possible explanation for respiratory side effectsM H Raasveld, F J Bemelman, P T Schellekens, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1996
99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphomaS F Vervoordeldonk, J Heikens, W T Goedemans, et al.
European Journal of Nuclear Medicine|August 1, 1996
Cardiac iodine-123 metaiodobenzylguanidine uptake in animals with diabetes mellitus and/or hypertensionE A Dubois, K L Kam, G A Somsen, et al.
Bone Marrow Transplantation|November 5, 2003
Nonlethal transfusion associated graft-versus-host disease in a severe combined immunodeficient patientA van Royen-Kerkhof, N M Wulffraat, S S M Kamphuis, et al.
Pageof 13